Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So et al

Affiliations

¹ Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.
² Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany.
³ Praxiszentrum St Bonifatius, Munchen, Germany.

Comment

Hendrik Schulze-Koops et al. Ann Rheum Dis. 2021 Jun.

. 2021 Jun;80(6):e98.

doi: 10.1136/annrheumdis-2020-218235. Epub 2020 Jun 24.

¹ Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.
² Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany.
³ Praxiszentrum St Bonifatius, Munchen, Germany.

No abstract available

Keywords: antirheumatic agents; autoimmune diseases; inflammation.

Conflict of interest statement

Competing interests: None declared.

Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Schulze-Koops H, et al. Ann Rheum Dis. 2020 Jun;79(6):840-842. doi: 10.1136/annrheumdis-2020-217628. Epub 2020 Apr 28. Ann Rheum Dis. 2020. PMID: 32345619 No abstract available.
Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak.
So H, Szeto CC, Tam LS. So H, et al. Ann Rheum Dis. 2021 Jun;80(6):e97. doi: 10.1136/annrheumdis-2020-218220. Epub 2020 Jun 24. Ann Rheum Dis. 2021. PMID: 32581085 No abstract available.